Acute liver failure

Miromatrix Announces FDA Clinical Hold on IND Application for miroliverELAP

Retrieved on: 
水曜日, 12月 14, 2022
Coronavirus, Clinical trial, Annual report, Communication, EDEN, Security (finance), Food, FDA, Acute liver failure, Maintenance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, IND, MIRO, Form 8-K, Pharmaceutical industry

The miroliverELAP IND application was submitted in mid-November.

Key Points: 
  • The miroliverELAP IND application was submitted in mid-November.
  • The FDA indicated they will provide an official clinical hold letter to Miromatrix within 30 days.
  • Miromatrix plans to provide additional updates pending communication with the FDA.
  • Forward‐looking statements contained in this press release include, but are not limited to: the FDA’s communication plans related to the clinical hold on miroliverELAP, our plans and expectations for discussions with the FDA and the outcomes from the discussions.

South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant

Retrieved on: 
木曜日, 9月 22, 2022
Transfer, Quotient, National, Joint Medical Service (Germany), Safety, Development, Small Business Innovation Research, Twitter, STTR, Nonsteroidal anti-inflammatory drug, Financial endowment, LinkedIn, Company, Acute liver failure, Analgesic, Drug overdose, Paracetamol, Patient, Texas Tech University Health Sciences Center, National Institute of Neurological Disorders and Stroke, Liver failure, Pain, SBIR, Liver, Pharmacology, The Best Science Fiction of the Year 3, Death, Pharmacokinetics, Unitus Seed Fund, Lists of diseases, Fever, Kidney, NIH, Chronic pain, NINDS, National Institute, Pharmaceutical industry, Poultry, Stroke

The NIH grant is entitled 'Novel non-narcotic analgesic for acute and chronic pain.'

Key Points: 
  • The NIH grant is entitled 'Novel non-narcotic analgesic for acute and chronic pain.'
  • Importantly, SRP-001 mirrors acetaminophen's clinically validated mechanism of action while simultaneously muting the biological activity that causes liver toxicity.
  • South Rampart Pharma is currently conducting an ongoing Phase 1 trial evaluating the safety, tolerability, and pharmacokinetics of SRP-001.
  • South Rampart Pharma's lead program, SRP-001, is a novel acetaminophen analog with a unique mechanism of action for its lack of liver toxicity present in acetaminophen.

South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain

Retrieved on: 
木曜日, 8月 25, 2022
Quotient, Drug overdose, Chronic pain, NINDS, Fever, CEO, Small Business Innovation Research, Paracetamol, FACS, Safety, Pharmacokinetics, Nonsteroidal anti-inflammatory drug, National Institute, Hepatotoxicity, Liver, IASP, Therapeutic index, Death, Kidney, Acute liver failure, STTR, DA, World Congress of Mountain Jews, LinkedIn, ER, NIH, Analgesic, Texas Tech University Health Sciences Center, Pharmacology, National Institute of Neurological Disorders and Stroke, SBIR, Company, Twitter, Lists of diseases, Unitus Seed Fund, International Association, Congress, International Association for the Study of Pain, Development, Patient, Pharmaceutical industry, Poultry, MD, Pain, Stroke

NEW ORLEANS, Aug. 25, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.

Key Points: 
  • NEW ORLEANS, Aug. 25, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.
  • South Rampart's CEO and Co-founder, Hernan Bazan, MD, FACS, will deliver the presentation.
  • The World Congress on Pain is the largest global gathering of pain professionals.
  • South Rampart Pharma is a clinical-stage life science company dedicated to advancing the safe treatment of pain by developing new small molecule solutions that can overcome many risks associated with current pain medicines.

South Rampart Pharma Announces Appointment of Josh Blacher as Chief Financial Officer

Retrieved on: 
火曜日, 8月 16, 2022
Quotient, CEO, Death, Acute liver failure, Facebook, Leadership, National academy, Research, Fever, Patient, Pharmacology, Chronic pain, TOOL, Partner, Development, Entrepreneurship, Liver, Small Business Innovation Research, Teva, Lehman Brothers, Risk, Joint Medical Service (Germany), Lists of diseases, Biotechnology, Safety, Teva Pharmaceuticals, Drug overdose, Pharmacokinetics, STTR, Science, DWS Group, National Institute, Morgan Stanley, Kidney, NINDS, Financial endowment, National Institute of Neurological Disorders and Stroke, NIH, Analgesic, Texas Tech University Health Sciences Center, INMED, National Academy of Sciences, Company, Twitter, Columbia Business School, NASDAQ, MBA, SBIR, LinkedIn, Nonsteroidal anti-inflammatory drug, IPO, Unitus Seed Fund, Paracetamol, Pharmaceutical industry, Poultry, Stroke, Pain

NEW ORLEANS, Aug. 16, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced the appointment of Josh Blacher as the company's Chief Financial Officer.

Key Points: 
  • NEW ORLEANS, Aug. 16, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced the appointment of Josh Blacher as the company's Chief Financial Officer.
  • Mr. Blacher brings to South Rampart Pharma over twenty years of leadership experience in senior positions in the healthcare and capital markets sectors.
  • Hernan Bazan, M.D., F.A.C.S., CEO and Co-Founder of South Rampart Pharma and The Endowed John Ochsner Professor of Surgery at the Ochsner Clinic, commented, "We are thrilled to welcome Josh to our team.
  • "I'm elated to join the South Rampart Pharma team to help it accomplish its corporate and clinical objectives."

The Worldwide Albumin Industry is Expected to Reach $8.9 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
水曜日, 7月 20, 2022
Health, Pharmaceutical, People, Serum albumin, Antibody, Awareness, Degenerative disease, Fatality, Acute respiratory distress syndrome, Acute liver failure, Trauma, Health, Hypovolemia, Adoption, CAGR, Bleeding, Drug development, Chronic liver disease, Therapy, Growth, Shock, Burns, Prevalence, Albumin, Hypoalbuminemia

The "Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021--2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021--2030" report has been added to ResearchAndMarkets.com's offering.
  • The Albumin market was valued at $4,813.5 million in 2020, and is estimated to reach $8,956.07 million by 2030, growing at a CAGR of 6.4% from 2021 to 2030.
  • Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used.
  • This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the albumin market.

Marler Clark Files First Lawsuit against FreshKampo in the Strawberry Hepatitis A Outbreak

Retrieved on: 
土曜日, 6月 4, 2022
Infection, Charles Arthur Brown, Burnham v. Superior Court of California, Macdonald, LLC, Nausea, Hepatitis, Pain scale, Fatigue, HEB, Canadian Food Inspection Agency, Symptoms of COVID-19, Liver, Hepatitis A, CDC, Pain, Fever, Public Health Agency of Canada, Multimedia, Lethargy, FDA, Acute liver failure, Food safety, SAN, Vomiting, Superior court, Diarrhea, Chills, McDonald's, Liver failure, Quiznos, Jaundice, Vaccine, Pharmaceutical industry, Subway, Chipotle, Costco

The plaintiffs are represented by Marler Clark , a Seattle based food safety law firm, and local counsel, Frederic L. Gordon.

Key Points: 
  • The plaintiffs are represented by Marler Clark , a Seattle based food safety law firm, and local counsel, Frederic L. Gordon.
  • "Strawberries grown outside the United States have been a source of hepatitis A illness in the past," said Bill Marler.
  • Marler Clark, The Food Safety Law Firm , is the nation's leading law firm representing victims of Hepatitis A outbreaks.
  • The Hepatitis A lawyers of Marler Clark have represented thousands of victims of Hepatitis A and other foodborne illness outbreaks and have recovered over $700 million for clients.

Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

Retrieved on: 
火曜日, 5月 31, 2022
Psilocybin, Acute liver failure, Cysteine, World, Glutathione, Infection, World Health Organization, Disorder, Autoimmune hepatitis, Clinical trial, Liver transplantation, COVID-19, Trial of the century, Reperfusion injury, Orphan drug, Research, FDA, CSE, RVV, Trustee, Hepatitis, Liver disease, WHO, Injury, Drug development, Therapy, Inflammation, Acquisition, Organ transplantation, Indiana University, Ischemia, IRI, Classification, GLOBE, Dietary supplement, Pharmaceutical industry, Company, CBD, Bucillamine, Cannabidiol

TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that in light of the growing cases of acute hepatitis in children reported by the World Health Organization (“WHO”), the Company will advance its drug pipeline for inflammatory liver disorders including Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis.

Key Points: 
  • The aetiology of this severe acute hepatitis remains unknown and under investigation; as the cases are more clinically severe and a higher proportion develops acute liver failure than previous reports of acute hepatitis of unknown aetiology in children.
  • At least 38 children have required a liver transplant, nine have died, and 99 cases pending classification, according to a statement from WHO (https://www.who.int/emergencies/disease-outbreak-news/item/DON-389).
  • The Company has a diverse product pipeline in development for rare inflammatory liver disorders, including receiving FDA orphan drug designation for Bucillamine to prevent ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease

Retrieved on: 
月曜日, 5月 23, 2022
Cancer, Copper, Cold, Company, Acute liver failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Enzyme, Family, Patient, Cirrhosis, Kayser–Fleischer ring, Rett syndrome, PTP, Cold Spring Harbor Laboratory, Degenerative disease, Liver, Marketing, Orphan drug, FDA, Brain, Nervous system, Media, Orphan Drug Act of 1983, Wilson's disease, Therapy, Genetic disorder, Person, Mental health, Diagnosis, CEO, GLOBE, Pharmaceutical industry, PTP1B

Today, the Company announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its clinical candidate DPM-1001, a small molecule PTP1B inhibitor that also has high specificity and high affinity for binding copper and is therefore being studied in Wilson Disease.

Key Points: 
  • Today, the Company announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its clinical candidate DPM-1001, a small molecule PTP1B inhibitor that also has high specificity and high affinity for binding copper and is therefore being studied in Wilson Disease.
  • Wilson Disease is a rare genetic disorder that prevents the body from removing copper, causing the metal to build up in the liver, brain, and corneas.
  • The Orphan Drug designation for DPM-1001 is another important milestone for DepYmed in the development of its PTP1B inhibitor class of drugs designed to treat rare diseases.
  • DepYmed is the first company to develop a new class of orally bioavailable drug candidates that act by inhibiting PTP1B, one of the most important PTP drug targets.

Worldwide Liver Disease Treatment Industry to 2027 - Featuring AbbVie, Emergent BioSolutions and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
金曜日, 4月 8, 2022
Health, Pharmaceutical, Adoption, Risk, Cholesterol, Hepatitis B virus, Hormone, Obesity, Nutrient, Cirrhosis, Degenerative disease, Institute of Liver and Biliary Sciences, Fatty liver disease, Growth, Public health, Genetics, Vaccine, Liver, Hepatitis, Research, Antibody, Hepatocellular carcinoma, Hypertension, Liver disease, Prevalence, Government, Industry, Diabetes, COVID-19, Cancer, Acute liver failure, Infection, R, Lists of diseases, Blood, Patient, Pharmaceutical industry, Dietary supplement, Potash

Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Key Points: 
  • Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.
  • It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients.
  • What has been the impact of COVID-19 on the global liver disease treatment market?
  • What is the structure of the global liver disease treatment market and who are the key players?

Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022

Retrieved on: 
木曜日, 2月 10, 2022
NASDAQ, Private Securities Litigation Reform Act, GLOBE, Industry, Form, Intellectual property, DaVita Inc., EDEN, Intention, Investor, SEC filing, Company, Acute liver failure, FDA, Technology, U.S. Securities and Exchange Commission, Safety, NYSE, Infection, Life, CDNA, Coronavirus, History, Event, MIRO, Nasdaq, Risk, 3D printing, Pharmaceutical industry, COVID-19

ET to celebrate National Donor Day and the Companys public listing last year on Nasdaq under the trading symbol MIRO.

Key Points: 
  • ET to celebrate National Donor Day and the Companys public listing last year on Nasdaq under the trading symbol MIRO.
  • Miromatrix CEO, Jeff Ross, Ph.D., will ring the closing bell alongside the Companys team and representatives from strategic investors, including Baxter (NYSE: BAX), CareDx (NASDAQ: CDNA), and DaVita (NYSE: DVA).
  • We are thrilled to celebrate such an important milestone for Miromatrix with our team, collaborators, and investors, said Jeff Ross, Ph.D., Miromatrix CEO.
  • Its especially appropriate on National Donor Day as we honor all those who have given and received the gift of life through the national donor program.